Tag Archive for: Insight

Changing the way we see CAR-T – Building out, not down

Co-founder and Chief Scientific Officer at Leucid Bio, Dr John Maher is revolutionising Chimeric Antigen Receptor (CAR) T-cell therapy, by designing CARs that are more powerful than predecessors and tough enough to tackle solid tumours. Dr Maher began his academic career at Trinity College, Dublin and has held numerous clinical, research and teaching positions at […]

Look after your heart month 2023

The sad death at the young age of 54 of David Jolicoeur, otherwise known as Trugoy the Dove, one of the founders of hip hop legends De La Soul, has helped to highlight to a wider audience the profound impact that congestive heart failure can have. David was a long term sufferer from this disease. […]

Scrip Asks… What does 2023 hold for Biopharma?

More than one hundred industry executives and experts provided insight into what to expect for the year ahead. Here’s what we’ve read so far… Technological Advances Today’s article explores the technological advances expected during 2023. Developments in data science and molecular biology drive expectations – for another year of breakthrough innovation in human therapeutics. However, […]

Dan Mahony & Gareth Powell – Global healthcare investing: Can hindsight hone the crystal ball for the future? A fireside chat moderated by Amy Brown, Evaluate Vantage

Dan Mahony and Gareth Powell are long time, successful life sciences and healthcare investors. They are luminaries of the UK and European healthcare ecosystem, who have been investing since the late 1990s and initially worked together at Polar Capital where together they set up the biotech and healthcare investment funds. Gareth is still Head of […]

Financing growth: Walking the tightrope – Annual Healthcare Investor Conference Insight

Financing growth: Walking the tightrope InsightIn the context of the particularly difficult public markets we have seen recently, Hannah Kuchler, Global Pharmaceuticals Correspondent at the Financial Times, chaired a panel of experts exploring what sources of capital are currently available to fund innovation and the development of new drugs, and what is needed to access […]